This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bettuzzi, S. Articles by Corti, A. Search for Related Content PubMed PubMed Citation Articles by Bettuzzi, S. Articles by Corti, A.

Successful Prediction of Prostate Cancer Recurrence by Gene Profiling in Combination with Clinical Data

A 5-year Follow-up Study¹

Dipartimento di Medicina Sperimentale, Plesso Biotecnologico Integrato, Università di Parma, Via Volturno 39-43100 Parma [S. B., A. C.]; Dipartimento di Scienze Biomediche, Università di Modena e Reggio Emilia, Via G. Campi 287-41100 Modena [M. S., D. D., S. A., P. D., A. C.]; and Ospedale Estense-S.Agostino, Divisione Urologia, Via S. Agostino 18-41100 Modena [M. B.], Italy

We show here that gene expression profiling, performed with conventional techniques and focused on a selected group of genes, when used in combination with standard clinical information, provides reliable prognostic prediction of prostate cancer (CaP). We showed previously that changes in the expression of metabolically related genes are involved in CaP progression. We then proceeded to search further for correlations between patients’ gene profiling and recurrence with a 5-year follow-up study conducted on the same cohort of patients in which the molecular data were obtained. CaP prognosis was first assessed on the basis of gene expression profiling alone; then the result was compared with the prediction obtained using clinical and pathological information (Gleason score, Tumor-Node-Metastasis staging, prostate volume, or prostate-specific antigen levels at the time of diagnosis). The best result was obtained with a selected combination of gene profiling and clinical/pathological parameters, which resulted in prediction of recurrence in 95.7% of patients.

This article has been cited by other articles:

				S. Carnevali, F. Luppi, D. D'Arca, A. Caporali, M. P. Ruggieri, M. V. Vettori, A. Caglieri, S. Astancolle, F. Panico, P. Davalli, et al. Clusterin Decreases Oxidative Stress in Lung Fibroblasts Exposed to Cigarette Smoke Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 393 - 399. [Abstract] [Full Text] [PDF]

				M. Scaltriti, L. Belloni, A. Caporali, P. Davalli, D. Remondini, F. Rizzi, S. Astancolle, A. Corti, and S. Bettuzzi Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling Carcinogenesis, May 1, 2006; 27(5): 1047 - 1053. [Abstract] [Full Text] [PDF]

				M. Scaltriti, A. Santamaria, R. Paciucci, and S. Bettuzzi Intracellular Clusterin Induces G2-M Phase Arrest and Cell Death in PC-3 Prostate Cancer Cells1 Cancer Res., September 1, 2004; 64(17): 6174 - 6182. [Abstract] [Full Text] [PDF]